[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_7148",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_7148"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00026"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "kineret is an interleukin 1 receptor antagonist indicated for rheumatoid arthritis ra reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards 1 1 cryopyrin associated periodic syndromes caps treatment of neonatal onset multisystem inflammatory disease nomid 1 2 kineret is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis ra in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs dmards kineret can be used alone or in combination with dmards other than tumor necrosis factor tnf blocking agents see warnings and precautions 5 2 kineret is indicated for the treatment of neonatal onset multisystem inflammatory disease nomid"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://w3id.org/um/neurodkg/SymptomaticReliefIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00026",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-12T12:56:30.695+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "TKmHDr+S1heELpvWg70G6WPxWUmYZAW5//r2s/5T/SLe4Pmzo0uhwXUnggDRnGfevQb1Ooms0+6TzRJfJHyBcgEw3l1PDXO7t9Z5pNcup7ir5Wd3sCesTpdg6KwUd4/0VDF6P5i9PTm89bFAGKAwYgGZkn98jFL/OcOshIhOajs="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAFhIgZdjjKeLs0DMocZruzFNTvkRyUqfZTzIn5p9QePg#pubinfo"
} ]